Last reviewed · How we verify
RCHOP
At a glance
| Generic name | RCHOP |
|---|---|
| Also known as | Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone 60 mg/m2 |
| Sponsor | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (PHASE2)
- Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. (PHASE2)
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (PHASE2)
- Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients (PHASE2)
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL (PHASE3)
- AZA Combined With RCHOP in P53-mutated DLBCL. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RCHOP CI brief — competitive landscape report
- RCHOP updates RSS · CI watch RSS
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI